Exagamglogene autotemcel for anemia, sickle cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 5 registered trials.

Why this status

  1. 23 Dec 2019: Trial registered, NCT04208529
  2. 20 Jan 2021: Trial started, NCT04208529
  3. 15 Apr 2022: Trial registered, NCT05329649
  4. 2 May 2022: Trial started, NCT05329649
  5. 28 Jul 2022: Trial registered, NCT05477563
  6. 2 Aug 2022: Trial started, NCT05477563

The trials

NCT03745287: A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

State
Completed
Phase
Phase 2 and Phase 3
People
63 taking part
Started
27 Nov 2018
Primary completion
7 Jul 2025
Arms
Exa-cel
Results
Posted on the registry
Papers
doi:10.1002/pbc.30274, doi:10.1002/pbc.30319, doi:10.1016/bs.pmbts.2021.01.025, doi:10.1016/j.jcyt.2022.08.003, doi:10.1016/j.jtct.2024.06.006, doi:10.1038/s41434-020-00192-z, doi:10.1056/nejmoa2031054, doi:10.1056/nejmoa2309676, doi:10.1182/bloodadvances.2025016701
  1. 19 Nov 2018: Trial registered
  2. 27 Nov 2018: Trial started
  3. 7 Jul 2025: Trial completed
  4. 16 Sep 2026: Trial results posted

NCT05329649: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

State
Under way
Phase
Phase 3
People
13 taking part
Started
2 May 2022
Primary completion
6 Jun 2027
Arms
CTX001
Results
None posted
Papers
doi:10.1056/nejmoa2603387
  1. 15 Apr 2022: Trial registered
  2. 2 May 2022: Trial started

NCT05477563: Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

State
Under way
Phase
Phase 3
People
26 planned
Started
2 Aug 2022
Primary completion
9 Jun 2027
Arms
CTX001
Results
None posted
  1. 28 Jul 2022: Trial registered
  2. 2 Aug 2022: Trial started

NCT05951205: Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype

State
Withdrawn before it started
Phase
Phase 3
People
0 taking part
Started
31 Jul 2027
Primary completion
31 Dec 2033
Arms
Exa-cel
Results
None posted
  1. 18 Jul 2023: Trial registered
  2. 25 Mar 2026: Trial withdrawn

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Exa-cel.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.